Karl Nägler
Directeur/Membre du Conseil chez Confo Therapeutics NV
Profil
Karl Nägler is currently a Director at Confo Therapeutics NV, a Director at Imcheck Therapeutics SAS, a Managing Partner at Wellington Partners GmbH, and a Board member at Gimv (Private Equity).
He was previously a Director-Executive Board at Horizon Therapeutics Switzerland GmbH, a Director at Intrexon ActoBiotics NV, a Director at Shogoo Pharmaceuticals KK, a Director at Prosonix Ltd., a Director at Covagen AG, a Director at Biom'Up SA, and a Director at Precirix NV.
Prior to that, he was a General Partner at Ventech SA and a Senior Associate at Atlas Venture GmbH.
Nägler holds a doctorate from the Technical University of Berlin and a graduate degree from Freie Universität Berlin.
Postes actifs de Karl Nägler
| Sociétés | Poste | Début |
|---|---|---|
| Gimv Germany | Private Equity Investor | 01/09/2011 |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 01/01/2020 |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Directeur/Membre du Conseil | - |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Directeur/Membre du Conseil | - |
Gimv (Private Equity)
 Gimv (Private Equity) Investment ManagersFinance Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium. | Directeur/Membre du Conseil | - |
Anciens postes connus de Karl Nägler
| Sociétés | Poste | Fin |
|---|---|---|
Ventech SA
 Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US. | Directeur/Membre du Conseil | 30/09/2011 |
Shogoo Pharmaceuticals KK
 Shogoo Pharmaceuticals KK Pharmaceuticals: MajorHealth Technology Shogoo Pharmaceuticals KK provides novel pharmaceutical products. It also licenses, develops, imports, exports, markets, and distributes pharmaceutical products. It provides medicines mainly for high unmet diseases. Shogoo Pharmaceuticals was founded in 2005 and is located in Tokyo, Japan. | Directeur/Membre du Conseil | 23/10/2009 |
Atlas Venture GmbH
 Atlas Venture GmbH Investment ManagersFinance Atlas Venture GmbH was the Munich office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in London and Paris, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The Munich office was established in the late 1990s. The group manages a range of venture capital funds. Atlas Venture GmbH was liquidated in 2009. | Private Equity Investor | 12/03/2009 |
Precirix NV
 Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium. | Directeur/Membre du Conseil | - |
| ░░░░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Karl Nägler
| Technical University of Berlin | Doctorate Degree |
| Freie Universität Berlin | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Atlas Venture GmbH
Atlas Venture GmbH Investment ManagersFinance Atlas Venture GmbH was the Munich office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in London and Paris, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The Munich office was established in the late 1990s. The group manages a range of venture capital funds. Atlas Venture GmbH was liquidated in 2009. | Finance |
Shogoo Pharmaceuticals KK
Shogoo Pharmaceuticals KK Pharmaceuticals: MajorHealth Technology Shogoo Pharmaceuticals KK provides novel pharmaceutical products. It also licenses, develops, imports, exports, markets, and distributes pharmaceutical products. It provides medicines mainly for high unmet diseases. Shogoo Pharmaceuticals was founded in 2005 and is located in Tokyo, Japan. | Health Technology |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Health Technology |
Ventech SA
Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US. | Finance |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
Biom'Up SA
 Biom'Up SA Medical SpecialtiesHealth Technology Biom'Up SA engages in the development of hemostatic product composed of patent-protected biopolymers. Its products include Hemoblast Bellows and Hemosnow. The company was founded by Patricia Forest, Sylvain Picot and Christian Gagnieu on February 21, 2005 and is headquartered in Lyon, France. | Health Technology |
Prosonix Ltd.
 Prosonix Ltd. Pharmaceuticals: MajorHealth Technology Prosonix Ltd. engages in the provision of inhaled respiratory medicines. The company was founded by Andre James Bush and David Hipkiss in 2006 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Health Technology |
| Gimv Germany | Finance |
Precirix NV
Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium. | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Health Technology |
Gimv (Private Equity)
Gimv (Private Equity) Investment ManagersFinance Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium. | Finance |
